ClinicalTrials.gov
History of Changes for Study: NCT00471497
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)
Latest version (submitted October 23, 2020) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 May 9, 2007 None (earliest Version on record)
2 September 18, 2007 Recruitment Status, Contacts/Locations and Study Status
3 September 27, 2007 Study Status and Study Identification
4 October 26, 2007 Study Status and Study Description
5 March 3, 2008 Study Status and Contacts/Locations
6 July 17, 2008 Contacts/Locations, Study Status and Sponsor/Collaborators
7 July 24, 2008 Contacts/Locations and Study Status
8 August 19, 2008 Study Status and Contacts/Locations
9 September 4, 2008 Study Status
10 October 3, 2008 Study Status
11 March 27, 2009 Recruitment Status, Contacts/Locations, Study Status and Sponsor/Collaborators
12 September 18, 2009 Study Status, References and Study Identification
13 September 27, 2009 Study Status
14 November 18, 2009 References and Study Status
15 January 27, 2010 Outcome Measures, Arms and Interventions, Study Status, Contacts/Locations, Study Design, Study Identification, Eligibility and Oversight
16 January 28, 2010 Outcome Measures and Study Status
17 May 27, 2010 Study Status and Contacts/Locations
18 March 7, 2012 Contacts/Locations, Study Design, Sponsor/Collaborators, Study Status, Conditions and Study Identification
19 April 12, 2012 Outcome Measures and Study Status
20 May 30, 2012 Recruitment Status, Contacts/Locations, Study Status, Outcome Measures and Conditions
21 July 18, 2012 Contacts/Locations and Study Status
22 June 13, 2013 Recruitment Status, Contacts/Locations, Study Status, Outcome Measures, Arms and Interventions, Study Design, Results, Eligibility and Conditions
23 October 14, 2013 Study Status
24 November 19, 2014 Contacts/Locations, Study Status, Arms and Interventions, Eligibility and Conditions
25 April 18, 2016 Contacts/Locations, Study Status and Study Design
26 November 27, 2016 Contacts/Locations, Study Status, Outcome Measures and Baseline Characteristics
27 May 25, 2017 Contacts/Locations, Study Status, Oversight, Baseline Characteristics, IPDSharing and Study Design
28 June 27, 2017 Study Status and Study Design
29 October 30, 2017 Contacts/Locations, Study Status and Study Design
30 July 29, 2018 Contacts/Locations, Study Status and References
31 October 26, 2018 Contacts/Locations, Study Status, Study Design and Study Description
32 December 6, 2018 Study Status
33 March 14, 2019 Contacts/Locations, Study Status and Study Design
34 April 3, 2019 Contacts/Locations, Study Status and Eligibility
35 April 25, 2019 IPDSharing, Study Status and Study Design
36 May 9, 2019 Study Status and Contacts/Locations
37 July 25, 2019 Study Status
38 September 9, 2019 Recruitment Status and Study Status
39 January 9, 2020 Contacts/Locations and Study Status
40 April 1, 2020 Contacts/Locations and Study Status
41 April 22, 2020 Contacts/Locations and Study Status
42 June 28, 2020 Contacts/Locations, Study Description, Study Status, IPDSharing, References and Eligibility
43 July 17, 2020 Study Status and Study Design
44 October 23, 2020 Adverse Events, Outcome Measures, Participant Flow, Baseline Characteristics, Contacts/Locations, More Information, Study Description, Study Status, Eligibility and Study Design
Comparison Format:
Scroll up to access the controls
Study NCT00471497
Submitted Date:  May 30, 2012 (v20)
Open or close this module Study Identification
Unique Protocol ID: CAMN107A2303
Brief Title: A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)
Official Title: A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Secondary IDs: 2007-000208-34 [Registry Identifier: EUDRACT]
Open or close this module Study Status
Record Verification: May 2012
Overall Status: Recruiting
Study Start: July 2007
Primary Completion: October 2018 [Anticipated]
Study Completion:
First Submitted: May 7, 2007
First Submitted that
Met QC Criteria:		 May 9, 2007
First Posted: May 10, 2007 [Estimate]
Last Update Submitted that
Met QC Criteria:		 May 30, 2012
Last Update Posted: May 31, 2012 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Novartis Pharmaceuticals
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring:
Open or close this module Study Description
Brief Summary: In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).
Detailed Description:
Open or close this module Conditions
Conditions: Myelogenous Leukemia, Chronic
Keywords: leukemia
bone marrow
leukemia symptoms
lukemia
cml
complete blood count
lymphocyte
blood cancer
leukocytes
chronic leukemia
bone marrow biopsy
leukemia research
leukemia cells
bone marrow disease
chronic myeloid leukemia
blood cancer symptoms
white blood cell diseases
chronic myelogenous leukemia
leukemia treatment
leukemia facts
leucemia
facts about leukemia
myelogenous leukemia
newly diagnosed CML
newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Single Group Assignment
Number of Arms: 3
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 845 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: nilotinib 300mg bid (investigating arm) Drug: nilotinib
Experimental: Nilotinb 400 mg bid (investigating arm) Drug: nilotinib
Experimental: imatinib 400mg QD (control arm) Drug: imatinib
Open or close this module Outcome Measures
Primary Outcome Measures:
1. To compare the rate of major molecular response (MMR)as measured by real-time quantitative polymerase chain reaction (RQ-PCR) at 12 months.
[ Time Frame: 12 months ]
Secondary Outcome Measures:
1. To compare the rate of durable MMR at 24 months.
[ Time Frame: 24 months ]
2. To compare the rate reduction in BCR-ABL transcript levels in nilotinib treatment arms with imatinib at 12 months.
[ Time Frame: 12 months ]
3. To compare the rate of complete cytogenetic response (CCyR) in nilotinib treatment arms with imatinib at 12 months.
[ Time Frame: 12 months ]
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion criteria:

  • Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.
  • Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome

Exclusion criteria:

  • Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib
  • Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
  • Uncontrolled or significant cardiovascular disease.
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
  • Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
  • Currently taking certain medications that could affect the rhythm of your heart.

Other protocol-defined inclusion/exclusion criteria may apply
Open or close this module Contacts/Locations
Central Contact Person: Novartis Pharmaceuticals
Telephone: +1(800)340-6843
Study Officials: Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Locations: United States, California
Novartis Investigative Site
[Active, not recruiting]
Los Angeles, California, United States, 90095
Novartis Investigative Site
[Withdrawn]
San Diego, California, United States
Novartis Investigative Site
[Terminated]
San Diego, California, United States
Novartis Investigative Site
[Active, not recruiting]
San Diego, California, United States
Novartis Investigative Site
[Active, not recruiting]
Vallejo, California, United States
Novartis Investigative Site
[Withdrawn]
Vallejo, California, United States
United States, Colorado
Novartis Investigative Site
[Withdrawn]
Aurora, Colorado, United States, 80045
Novartis Investigative Site
[Active, not recruiting]
Greenwood Village, Colorado, United States
United States, Connecticut
Novartis Investigative Site
[Withdrawn]
New Haven, Connecticut, United States, 06520
United States, Florida
Novartis Investigative Site
[Active, not recruiting]
Fort Myers, Florida, United States, 33901
Novartis Investigative Site
[Withdrawn]
Jacksonville, Florida, United States, 32258
Novartis Investigative Site
[Active, not recruiting]
Miami, Florida, United States, 33176
Novartis Investigative Site
[Active, not recruiting]
New Port Richey, Florida, United States, 34655
Novartis Investigative Site
[Active, not recruiting]
Ocoee, Florida, United States, *see dep*
United States, Georgia
Novartis Investigative Site
[Withdrawn]
Marietta, Georgia, United States, 30060
United States, Illinois
Novartis Investigative Site
[Active, not recruiting]
Chicago, Illinois, United States, 60546
Novartis Investigative Site
[Withdrawn]
Chicago, Illinois, United States, 60611-3308
Novartis Investigative Site
[Withdrawn]
Chicago, Illinois, United States, 60612
United States, Indiana
Novartis Investigative Site
[Active, not recruiting]
Beach Grove, Indiana, United States, 46107
Novartis Investigative Site
[Withdrawn]
Indianapolis, Indiana, United States, 46227
United States, Iowa
Novartis Investigative Site
[Active, not recruiting]
Iowa City, Iowa, United States, 52242
United States, Kansas
Novartis Investigative Site
[Active, not recruiting]
Overland Park, Kansas, United States, 66210
United States, Louisiana
Novartis Investigative Site
[Active, not recruiting]
New Orleans, Louisiana, United States, 70115
United States, Michigan
Novartis Investigative Site
[Withdrawn]
Ann Arbor, Michigan, United States, 48109
Novartis Investigative Site
[Active, not recruiting]
Lansing, Michigan, United States
Novartis Investigative Site
[Withdrawn]
Southfield, Michigan, United States
United States, Minnesota
Novartis Investigative Site
[Withdrawn]
Minneapolis, Minnesota, United States, 55404
Novartis Investigative Site
[Withdrawn]
Rochester, Minnesota, United States, 55905
United States, Missouri
Novartis Investigative Site
[Completed]
Columbia, Missouri, United States, 65201
Novartis Investigative Site
[Withdrawn]
St. Joseph, Missouri, United States, 64507
Novartis Investigative Site
[Withdrawn]
St. Louis, Missouri, United States, 63136
Novartis Investigative Site
[Completed]
St. Louis, Missouri, United States, 63136
United States, New Jersey
Novartis Investigative Site
[Active, not recruiting]
Hackensack, New Jersey, United States, 07601
United States, New York
Novartis Investigative Site
[Withdrawn]
Buffalo, New York, United States, 14263
Novartis Investigative Site
[Active, not recruiting]
New York, New York, United States, 10021
United States, North Carolina
Novartis Investigative Site
[Active, not recruiting]
Chapel Hill, North Carolina, United States, 27514
Novartis Investigative Site
[Withdrawn]
Durham, North Carolina, United States, 27710
Novartis Investigative Site
[Active, not recruiting]
Raleigh, North Carolina, United States, 27609
Novartis Investigative Site
[Active, not recruiting]
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Novartis Investigative Site
[Active, not recruiting]
Cincinnati, Ohio, United States, 45219
Novartis Investigative Site
[Withdrawn]
Cincinnati, Ohio, United States, 45242
Novartis Investigative Site
[Withdrawn]
Cleveland, Ohio, United States, 44106
Novartis Investigative Site
[Active, not recruiting]
Cleveland, Ohio, United States, 44195
United States, Oregon
Novartis Investigative Site
[Active, not recruiting]
Portland, Oregon, United States, 97210
United States, South Carolina
Novartis Investigative Site
[Active, not recruiting]
Greenville, South Carolina, United States, 29605
United States, Tennessee
Novartis Investigative Site
[Active, not recruiting]
Chattanooga, Tennessee, United States, 37404
Novartis Investigative Site
[Withdrawn]
Germantown, Tennessee, United States, 38138
Novartis Investigative Site
[Active, not recruiting]
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis Investigative Site
[Withdrawn]
Bedford, Texas, United States, 76022
Novartis Investigative Site
[Active, not recruiting]
Dallas, Texas, United States, 75230
Novartis Investigative Site
[Withdrawn]
Dallas, Texas, United States, 75246
Novartis Investigative Site
[Withdrawn]
Dallas, Texas, United States, 75390-8527
Novartis Investigative Site
[Withdrawn]
Houston, Texas, United States, 77030-4009
Novartis Investigative Site
[Withdrawn]
Houston, Texas, United States, 77030
Novartis Investigative Site
[Withdrawn]
Odessa, Texas, United States, 79761
Novartis Investigative Site
[Active, not recruiting]
San Antonio, Texas, United States, 78229
Novartis Investigative Site
[Withdrawn]
San Antonio, Texas, United States, 78229
Novartis Investigative Site
[Active, not recruiting]
Tyler, Texas, United States, 75702
Novartis Investigative Site
[Withdrawn]
Waco, Texas, United States, 76712
United States, Utah
Novartis Investigative Site
[Active, not recruiting]
Salt Lake City, Utah, United States, 84103
United States, Virginia
Novartis Investigative Site
[Withdrawn]
*see Various Departments*, Virginia, United States
Novartis Investigative Site
[Withdrawn]
Charlottesville, Virginia, United States, 22908
United States, Washington
Novartis Investigative Site
[Withdrawn]
Spokane, Washington, United States, 99202
Algeria
Novartis Investigative Site
[Withdrawn]
Alger, Algeria, 016000
Argentina
Novartis Investigative Site
[Withdrawn]
Buenos Aires, Argentina, C1114AAN
Novartis Investigative Site
[Active, not recruiting]
Buenos Aires, Argentina, C1221ADC
Novartis Investigative Site
[Withdrawn]
Buenos Aires, Argentina, C1280AEB
Novartis Investigative Site
[Withdrawn]
Buenos Aires, Argentina, C1431FWO
Argentina, Buenos Aires
Novartis Investigative Site
[Withdrawn]
La Plata, Buenos Aires, Argentina, B1900AWT
Novartis Investigative Site
[Active, not recruiting]
La Plata, Buenos Aires, Argentina, B1902AVG
Novartis Investigative Site
[Withdrawn]
Mar del Plata, Buenos Aires, Argentina, B7600BZY
Austria
Novartis Investigative Site
[Active, not recruiting]
Salzburg, Austria, 5020
Novartis Investigative Site
[Withdrawn]
Wels, Austria, A-4600
Novartis Investigative Site
[Active, not recruiting]
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
[Active, not recruiting]
Bruxelles, Belgium, 1000
Novartis Investigative Site
[Active, not recruiting]
Charleroi, Belgium, 6000
Novartis Investigative Site
[Active, not recruiting]
Gent, Belgium, 9000
Novartis Investigative Site
[Active, not recruiting]
Godinne, Belgium, 5530
Novartis Investigative Site
[Active, not recruiting]
Leuven, Belgium, 3000
Brazil, CE
Novartis Investigative Site
[Withdrawn]
Fortaleza, CE, Brazil, 60440-261
Brazil, DF
Novartis Investigative Site
[Active, not recruiting]
Brasilia, DF, Brazil, 70330-150
Brazil, PR
Novartis Investigative Site
[Active, not recruiting]
Curitiba, PR, Brazil, 80060-900
Brazil, RJ
Novartis Investigative Site
[Active, not recruiting]
Rio de Janeiro, RJ, Brazil, 20211-030
Brazil, RS
Novartis Investigative Site
[Withdrawn]
Porto Alegre, RS, Brazil, 90035-903
Brazil, SP
Novartis Investigative Site
[Active, not recruiting]
Campinas, SP, Brazil, 13083-970
Novartis Investigative Site
[Active, not recruiting]
Jaú, SP, Brazil, 17210-080
Novartis Investigative Site
[Active, not recruiting]
São Paulo, SP, Brazil, 01224-000
Novartis Investigative Site
[Active, not recruiting]
São Paulo, SP, Brazil, 01401-901
Novartis Investigative Site
[Active, not recruiting]
São Paulo, SP, Brazil, 05403-000
Canada
Novartis Investigative Site
[Active, not recruiting]
Quebec, Canada, G2R 2J6
Canada, Alberta
Novartis Investigative Site
[Terminated]
Vancouver, Alberta, Canada, V5Z 4E6
Canada, British Columbia
Novartis Investigative Site
[Active, not recruiting]
Vancouver, British Columbia, Canada, V5Z 4E3
Canada, Nova Scotia
Novartis Investigative Site
[Withdrawn]
Halifax, Nova Scotia, Canada, B3H 2Y6
Canada, Ontario
Novartis Investigative Site
[Active, not recruiting]
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Novartis Investigative Site
[Withdrawn]
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
[Withdrawn]
Montreal, Quebec, Canada, H2W 1S6
Novartis Investigative Site
[Active, not recruiting]
Québec, Quebec, Canada, G1J 1Z4
Colombia
Novartis Investigative Site
[Active, not recruiting]
Bogotá, Colombia
Czech Republic
Novartis Investigative Site
[Active, not recruiting]
Praha 2, Czech Republic, 128 20
Czech Republic, CZE
Novartis Investigative Site
[Active, not recruiting]
Olomouc, CZE, Czech Republic, 775 20
Denmark
Novartis Investigative Site
[Active, not recruiting]
Copenhagen, Denmark, DK-2100
Novartis Investigative Site
[Withdrawn]
Herlev, Denmark, 2730
Novartis Investigative Site
[Active, not recruiting]
Vejle, Denmark, DK-7100
Egypt
Novartis Investigative Site
[Active, not recruiting]
Cairo, Egypt
Finland
Novartis Investigative Site
[Active, not recruiting]
HUS Helsinki, Finland, FIN-00029
Novartis Investigative Site
[Active, not recruiting]
Turku, Finland, FIN-20521
France
Novartis Investigative Site
[Active, not recruiting]
Angers, France, 49 033
Novartis Investigative Site
[Active, not recruiting]
Bordeaux, France, 33076
Novartis Investigative Site
[Active, not recruiting]
Créteil, France, 94010
Novartis Investigative Site
[Active, not recruiting]
Grenoble, France, 38043
Novartis Investigative Site
[Active, not recruiting]
Lille, France, 59037
Novartis Investigative Site
[Active, not recruiting]
Marseille, France, 13273
Novartis Investigative Site
[Active, not recruiting]
Nantes, France, 44035
Novartis Investigative Site
[Active, not recruiting]
Nice Cedex, France, 06202
Novartis Investigative Site
[Active, not recruiting]
Paris, France, 75475
Novartis Investigative Site
[Active, not recruiting]
Pierre-Benite Cédex, France, F-69495
Novartis Investigative Site
[Active, not recruiting]
Poitiers, France, Poitiers
Novartis Investigative Site
[Active, not recruiting]
Rennes, France, 35019
Novartis Investigative Site
[Active, not recruiting]
Saint Priest en Jarez Cedex, France, 42271
Novartis Investigative Site
[Withdrawn]
Strasbourg, France, 67098
Novartis Investigative Site
[Active, not recruiting]
Toulouse cedex 9, France, 31059
Novartis Investigative Site
[Active, not recruiting]
Vandoeuvre les Nancy, France, 54511
France, Cedex
Novartis Investigative Site
[Active, not recruiting]
Caen, Cedex, France, 14033
Germany
Novartis Investigative Site
[Active, not recruiting]
Berlin, Germany, 13353
Novartis Investigative Site
[Active, not recruiting]
Duesseldorf, Germany, 40225
Novartis Investigative Site
[Active, not recruiting]
Eisenach, Germany, 99817
Novartis Investigative Site
[Active, not recruiting]
Frankfurt, Germany, 60590
Novartis Investigative Site
[Withdrawn]
Greifswald, Germany, 17475
Novartis Investigative Site
[Withdrawn]
Guestrow, Germany, 18273
Novartis Investigative Site
[Active, not recruiting]
Hamburg, Germany, 20246
Novartis Investigative Site
[Active, not recruiting]
Kiel, Germany, D-24116
Novartis Investigative Site
[Active, not recruiting]
Koeln, Germany, 50937
Novartis Investigative Site
[Withdrawn]
Leer, Germany, 26789
Novartis Investigative Site
[Active, not recruiting]
Leipzig, Germany, 04103
Novartis Investigative Site
[Active, not recruiting]
Mannheim, Germany, 68169
Novartis Investigative Site
[Active, not recruiting]
Muenchen, Germany, 81675
Novartis Investigative Site
[Active, not recruiting]
Ulm, Germany, 89081
Hong Kong
Novartis Investigative Site
[Active, not recruiting]
Hong Kong, Hong Kong
Hungary
Novartis Investigative Site
[Active, not recruiting]
Budapest, Hungary, 1097
Novartis Investigative Site
[Withdrawn]
Debrecen, Hungary, 4032
Italy
Novartis Investigative Site
[Withdrawn]
Modena, Italy, 41100
Novartis Investigative Site
[Active, not recruiting]
Napoli, Italy, 80131
Novartis Investigative Site
[Active, not recruiting]
Napoli, Italy, 80132
Novartis Investigative Site
[Active, not recruiting]
Perugia, Italy, 06129
Italy, AL
Novartis Investigative Site
[Active, not recruiting]
Alessandria, AL, Italy, 15100
Italy, AN
Novartis Investigative Site
[Active, not recruiting]
Ancona, AN, Italy, 60126
Italy, BA
Novartis Investigative Site
[Terminated]
Bari, BA, Italy, 70124
Italy, BG
Novartis Investigative Site
[Active, not recruiting]
Bergamo, BG, Italy, 24128
Italy, BO
Novartis Investigative Site
[Active, not recruiting]
Bologna, BO, Italy, 40138
Italy, CT
Novartis Investigative Site
[Active, not recruiting]
Catania, CT, Italy, 95124
Italy, FI
Novartis Investigative Site
[Active, not recruiting]
Firenze, FI, Italy, 50134
Italy, GE
Novartis Investigative Site
[Active, not recruiting]
Genova, GE, Italy, 16132
Italy, MI
Novartis Investigative Site
[Active, not recruiting]
Milano, MI, Italy, 20162
Italy, PE
Novartis Investigative Site
[Active, not recruiting]
Pescara, PE, Italy, 65124
Italy, PI
Novartis Investigative Site
[Active, not recruiting]
Pisa, PI, Italy, 56126
Italy, PU
Novartis Investigative Site
[Withdrawn]
Pesaro, PU, Italy, 61100
Italy, PV
Novartis Investigative Site
[Active, not recruiting]
Pavia, PV, Italy, 27100
Italy, RC
Novartis Investigative Site
[Active, not recruiting]
Reggio Calabria, RC, Italy, 89124
Italy, RM
Novartis Investigative Site
[Active, not recruiting]
Roma, RM, Italy, 00133
Novartis Investigative Site
[Active, not recruiting]
Roma, RM, Italy, 00144
Novartis Investigative Site
[Active, not recruiting]
Roma, RM, Italy, 00161
Italy, SI
Novartis Investigative Site
[Active, not recruiting]
Siena, SI, Italy, 53100
Italy, TO
Novartis Investigative Site
[Withdrawn]
Orbassano, TO, Italy, 10043
Italy, UD
Novartis Investigative Site
[Active, not recruiting]
Udine, UD, Italy, 33100
Japan
Novartis Investigative Site
[Active, not recruiting]
Akita, Japan, 010-8543
Novartis Investigative Site
[Active, not recruiting]
Chiba, Japan, 260-8677
Novartis Investigative Site
[Active, not recruiting]
Hiroshima, Japan, 734-8551
Novartis Investigative Site
[Active, not recruiting]
Kumamoto, Japan, 860-8556
Novartis Investigative Site
[Active, not recruiting]
Nagasaki, Japan, 852-8501
Novartis Investigative Site
[Active, not recruiting]
Niigata, Japan, 951-8520
Novartis Investigative Site
[Active, not recruiting]
Osaka, Japan, 545-8586
Novartis Investigative Site
[Active, not recruiting]
Saitama, Japan, 330-8503
Japan, Aichi
Novartis Investigative Site
[Active, not recruiting]
Nagoya, Aichi, Japan, 453-8511
Novartis Investigative Site
[Terminated]
Nagoya, Aichi, Japan, 466-8560
Japan, Gunma
Novartis Investigative Site
[Active, not recruiting]
Maebashi, Gunma, Japan, 371-0821
Novartis Investigative Site
[Active, not recruiting]
Maebashi, Gunma, Japan, 371-8511
Japan, Hokkaido
Novartis Investigative Site
[Active, not recruiting]
Sapporo, Hokkaido, Japan, 003-0006
Novartis Investigative Site
[Active, not recruiting]
Sapporo, Hokkaido, Japan, 060-8648
Japan, Hyogo
Novartis Investigative Site
[Active, not recruiting]
Nishinomiya, Hyogo, Japan, 663-8501
Japan, Ibaraki
Novartis Investigative Site
[Active, not recruiting]
Tsukuba, Ibaraki, Japan, 305-8576
Japan, Ishikawa
Novartis Investigative Site
[Active, not recruiting]
Kanazawa, Ishikawa, Japan, 920-8641
Japan, Mie
Novartis Investigative Site
[Active, not recruiting]
Tsu, Mie, Japan, 514-8507
Japan, Osaka
Novartis Investigative Site
[Active, not recruiting]
OsakaSayama, Osaka, Japan, 589-8511
Novartis Investigative Site
[Active, not recruiting]
Suita, Osaka, Japan, 565-0871
Japan, Saitama
Novartis Investigative Site
[Active, not recruiting]
Hidaka, Saitama, Japan, 350-1241
Japan, Shizuoka
Novartis Investigative Site
[Active, not recruiting]
Hamamatsu, Shizuoka, Japan, 431-3192
Japan, Tochigi
Novartis Investigative Site
[Active, not recruiting]
Simotsuke-city, Tochigi, Japan, 329-0498
Japan, Tokyo
Novartis Investigative Site
[Active, not recruiting]
Bunkyo-ku, Tokyo, Japan, 113-8519
Novartis Investigative Site
[Active, not recruiting]
Bunkyo-ku, Tokyo, Japan, 113-8655
Novartis Investigative Site
[Active, not recruiting]
Chuo-ku, Tokyo, Japan, 104-0045
Novartis Investigative Site
[Withdrawn]
Minato-ku, Tokyo, Japan, 105-8471
Novartis Investigative Site
[Withdrawn]
Minato-ku, Tokyo, Japan, 108-8639
Novartis Investigative Site
[Active, not recruiting]
Shinagawa-ku, Tokyo, Japan, 141-8625
Novartis Investigative Site
[Active, not recruiting]
Shinjuku-ku, Tokyo, Japan, 160-0023
Novartis Investigative Site
[Active, not recruiting]
Shinjuku-ku, Tokyo, Japan, 160-8582
Korea, Republic of
Novartis Investigative Site
[Withdrawn]
Seoul, Korea, Republic of, 150-713
Novartis Investigative Site
[Active, not recruiting]
Seoul, Korea, Republic of, 738-736
Novartis Investigative Site
[Active, not recruiting]
Taegu, Korea, Republic of, 700 - 721
Korea, Republic of, Jeollanam-do
Novartis Investigative Site
[Active, not recruiting]
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809
Korea, Republic of, Korea
Novartis Investigative Site
[Active, not recruiting]
Seoul, Korea, Korea, Republic of, 110 744
Novartis Investigative Site
[Active, not recruiting]
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site
[Active, not recruiting]
Seoul, Korea, Korea, Republic of, 137-701
Malaysia
Novartis Investigative Site
[Active, not recruiting]
Selangor, Malaysia, 68000
Mexico, Distrito Federal
Novartis Investigative Site
[Active, not recruiting]
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site
[Withdrawn]
México, Distrito Federal, Mexico, 02990
Novartis Investigative Site
[Withdrawn]
México, Distrito Federal, Mexico, 03100
Novartis Investigative Site
[Withdrawn]
México, Distrito Federal, Mexico, 06720
Novartis Investigative Site
[Withdrawn]
México, Distrito Federal, Mexico, 14080
Mexico, Jalisco
Novartis Investigative Site
[Withdrawn]
Zapopan, Jalisco, Mexico, 45170
Mexico, Nuevo León
Novartis Investigative Site
[Active, not recruiting]
Monterrey, Nuevo León, Mexico, 64450
Netherlands
Novartis Investigative Site
[Active, not recruiting]
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
[Withdrawn]
Rotterdam, Netherlands, 3075 EA
Norway
Novartis Investigative Site
[Active, not recruiting]
Oslo, Norway, NO-0027
Novartis Investigative Site
[Active, not recruiting]
Trondheim, Norway, 7006
Poland
Novartis Investigative Site
[Active, not recruiting]
Katowice, Poland, 40032
Novartis Investigative Site
[Active, not recruiting]
Lublin, Poland, 20-081
Novartis Investigative Site
[Active, not recruiting]
Rzeszow, Poland, 35-055
Novartis Investigative Site
[Active, not recruiting]
Warszawa, Poland, 02-097
Novartis Investigative Site
[Active, not recruiting]
Wroclaw, Poland, 50-367
Portugal
Novartis Investigative Site
[Terminated]
Lisboa, Portugal, 1099 - 023
Russian Federation
Novartis Investigative Site
[Active, not recruiting]
Moscow, Russian Federation, 125167
Novartis Investigative Site
[Active, not recruiting]
Novosibirsk, Russian Federation, 630091
Novartis Investigative Site
[Active, not recruiting]
St.- Petersburg, Russian Federation, 197022
Singapore
Novartis Investigative Site
[Active, not recruiting]
Singapore, Singapore, 119228
Novartis Investigative Site
[Active, not recruiting]
Singapore, Singapore, 169608
Slovakia
Novartis Investigative Site
[Active, not recruiting]
Bratislava, Slovakia, 851 07
Slovakia, Slovak Republic
Novartis Investigative Site
[Active, not recruiting]
Bratislava, Slovak Republic, Slovakia, 833 10
South Africa
Novartis Investigative Site
[Active, not recruiting]
Bloemfontein, South Africa, 901
Novartis Investigative Site
[Withdrawn]
Cape Town, South Africa, 7500
Novartis Investigative Site
[Active, not recruiting]
Cape Town, South Africa, 7925
Novartis Investigative Site
[Active, not recruiting]
Johannesburg, South Africa, 2195
Novartis Investigative Site
[Active, not recruiting]
Pretoria, South Africa, 0001
Novartis Investigative Site
[Active, not recruiting]
Pretoria, South Africa, 0027
Spain
Novartis Investigative Site
[Withdrawn]
Barcelona, Spain, 08025
Novartis Investigative Site
[Active, not recruiting]
Madrid, Spain, 28006
Novartis Investigative Site
[Withdrawn]
Madrid, Spain, 28007
Novartis Investigative Site
[Active, not recruiting]
Madrid, Spain, 28034
Novartis Investigative Site
[Terminated]
Madrid, Spain, 28041
Novartis Investigative Site
[Active, not recruiting]
Madrid, Spain, 28046
Novartis Investigative Site
[Withdrawn]
Murcia, Spain, 30008
Novartis Investigative Site
[Completed]
Valencia, Spain, 46026
Novartis Investigative Site
[Active, not recruiting]
Zaragoza, Spain, 50009
Novartis Investigative Site
[Withdrawn]
Zaragoza, Spain, 50009
Spain, Andalucía
Novartis Investigative Site
[Active, not recruiting]
Granada, Andalucía, Spain, 18014
Novartis Investigative Site
[Active, not recruiting]
Málaga, Andalucía, Spain, 29010
Novartis Investigative Site
[Withdrawn]
Sevilla, Andalucía, Spain, 41013
Spain, Cantabria
Novartis Investigative Site
[Active, not recruiting]
Santander, Cantabria, Spain, 39008
Spain, Castilla y Leon
Novartis Investigative Site
[Active, not recruiting]
Salamanca, Castilla y Leon, Spain, 37007
Spain, Cataluña
Novartis Investigative Site
[Withdrawn]
Badalona, Cataluña, Spain, 08916
Novartis Investigative Site
[Active, not recruiting]
Barcelona, Cataluña, Spain, 08035
Novartis Investigative Site
[Active, not recruiting]
Barcelona, Cataluña, Spain, 08036
Novartis Investigative Site
[Active, not recruiting]
Hospitalet de LLobregat, Cataluña, Spain, 08907
Spain, Comunidad Valenciana
Novartis Investigative Site
[Active, not recruiting]
Valencia, Comunidad Valenciana, Spain, 46010
Spain, Galicia
Novartis Investigative Site
[Active, not recruiting]
La Coruña, Galicia, Spain, 15006
Novartis Investigative Site
[Active, not recruiting]
Santiago de Compostela, Galicia, Spain, 15706
Spain, Islas Baleares
Novartis Investigative Site
[Withdrawn]
Palma De Mallorca, Islas Baleares, Spain, 07014
Spain, Murcia
Novartis Investigative Site
[Active, not recruiting]
Elche, Murcia, Spain, 03202
Spain, País Vasco
Novartis Investigative Site
[Active, not recruiting]
Bilbao, País Vasco, Spain, 48013
Novartis Investigative Site
[Active, not recruiting]
San Sebastian, País Vasco, Spain, 20014
Spain, Santa Cruz de Tenerife
Novartis Investigative Site
[Active, not recruiting]
La Laguna, Santa Cruz de Tenerife, Spain, 38320
Sweden
Novartis Investigative Site
[Active, not recruiting]
Göteborg, Sweden, SE-413 45
Novartis Investigative Site
[Completed]
Luleå, Sweden, SE-971 80
Novartis Investigative Site
[Active, not recruiting]
Lund, Sweden, SE-221 85
Novartis Investigative Site
[Active, not recruiting]
Stockholm, Sweden, SE-141 86
Novartis Investigative Site
[Active, not recruiting]
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
[Active, not recruiting]
Sundsvall, Sweden, SE-851 86
Novartis Investigative Site
[Active, not recruiting]
Umeå, Sweden, SE-901 85
Novartis Investigative Site
[Active, not recruiting]
Uppsala, Sweden, SE-751 85
Novartis Investigative Site
[Completed]
Örebro, Sweden, SE-701 85
Switzerland
Novartis Investigative Site
[Withdrawn]
Bern, Switzerland, 3010
Novartis Investigative Site
[Active, not recruiting]
Genève, Switzerland, 1211
Novartis Investigative Site
[Withdrawn]
St. Gallen, Switzerland, 9007
Taiwan
Novartis Investigative Site
[Active, not recruiting]
Lin-Ko, Taiwan, 33305
Novartis Investigative Site
[Withdrawn]
Liouying Township, Taiwan
Novartis Investigative Site
[Active, not recruiting]
Niaosong Township, Taiwan, 83301
Novartis Investigative Site
[Withdrawn]
Taichung, Taiwan, 40705
Novartis Investigative Site
[Active, not recruiting]
Taipei, Taiwan, 10002
Thailand
Novartis Investigative Site
[Active, not recruiting]
Bangkok, Thailand, 10330
Novartis Investigative Site
[Active, not recruiting]
Bangkok, Thailand, 10400
Novartis Investigative Site
[Active, not recruiting]
Bangkok, Thailand, 10700
Turkey
Novartis Investigative Site
[Active, not recruiting]
Adana, Turkey, 01330
Novartis Investigative Site
[Withdrawn]
Altunizade, Turkey, 34662
Novartis Investigative Site
[Active, not recruiting]
Ankara, Turkey, 06500
Novartis Investigative Site
[Active, not recruiting]
Istanbul, Turkey, 34303
Novartis Investigative Site
[Active, not recruiting]
Izmir, Turkey, 35340
United Kingdom
Novartis Investigative Site
[Active, not recruiting]
Glasgow - Scotland, United Kingdom, G12 OYN
Novartis Investigative Site
[Active, not recruiting]
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
[Active, not recruiting]
Liverpool, United Kingdom, L7 8XP
Novartis Investigative Site
[Recruiting]
London, United Kingdom, W12 0NN
Novartis Investigative Site
[Active, not recruiting]
Nottingham, United Kingdom, NG5 1BP
Venezuela, Distrito Capital
Novartis Investigative Site
[Active, not recruiting]
Caracas, Distrito Capital, Venezuela, 1010
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links:
Available IPD/Information:
Scroll up to access the controls Scroll to the Study top
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services